The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
Open accessThe DOI matches its Crossref record; 78 of the 79 references it cites were found in a registry or an index.
Abstract
Diabetes is a common cause of chronic kidney disease (CKD), but in aggregate, non-diabetic diseases account for a higher proportion of cases of CKD than diabetes in many parts of the world. Inhibition of the renin-angiotensin system reduces the risk of kidney disease progression and treatments that lower blood pressure (BP) or low-density lipoprotein cholesterol reduce cardiovascular (CV) risk in this population. Nevertheless, despite such interventions, considerable risks for kidney and CV complications remain. Recently, large placebo-controlled outcome trials have shown that sodium-glucose co-transporter-2 (SGLT-2) inhibitors reduce the risk of CV disease (including CV death and hospitalization for heart failure) in people with type 2 diabetes who are at high risk of atherosclerotic disease, and these effects were largely independent of improvements in hyperglycaemia, BP and body weight. In the kidney, increased sodium delivery to the macula densa mediated by SGLT-2 inhibition has the potential to reduce intraglomerular pressure, which may explain why SGLT-2 inhibitors reduce albuminuria and appear to slow kidney function decline in people with diabetes. Importantly, in the trials completed to date, these benefits appeared to be maintained at lower levels of kidney function, despite attenuation of glycosuric effects, and did not appear to be dependent on ambient hyperglycaemia. There is therefore a rationale for studying the cardio-renal effects of SGLT-2 inhibition in people at risk of CV disease and hyperfiltration (i.e. those with substantially reduced nephron mass and/or albuminuria), irrespective of whether they have diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The EMPA-Kidney trial, although not yet published, also enrolled patients with an eGFR as low as 20 ml/min per 1.73 m 2 and was stopped early due to clear evidence of ef fi cacy. 95”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [95]
Experimental — accuracy not yet measuredIn the citing paper
“There is substantial overlap between the FLOW population and the populations studied in the dedicated kidney outcome studies with SGLT2is (CREDENCE, DAPA-CKD and EMPA-KIDNEY) [15,30,32]”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Self-citationCanagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987 · cited 2×
“Angiotensin II is one key mediator of efferent arterio-lar resistance and ACEi/ARBs effectively reduce intraglomerular pressure and slow kidney disease progression through a reduction of efferent vascular resistance [11, 12].”
Chronic kidney disease: global dimension and perspectives
Jha, V., Garcia-Garcia, G., Iseki, K., Li, Z., Naicker, S., Plattner, B., Saran, R., Wang, A. Y.-M., & Yang, C.-W. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60687-x · Cited by 4,383 · cited 1×
“Worldwide, diabetic kidney disease accounts for a large proportion of advanced CKD (i.e. Stages 4 and 5), but the proportion of those without diabetes still ranges from (cid:2) 50 to 70% [4, 5].”
Ettehad, D., Emdin, C. A., Kiran, A., Anderson, S. G., Callender, T., Emberson, J., Chalmers, J., Rodgers, A., & Rahimi, K. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01225-8 · Cited by 3,755 · cited 1×
“Trials of intensification of blood pressure (BP) lowering also suggest small benefits on CKD progression may perhaps exist among those with proteinuria [18–21].”
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Self-citationKlahr, S., Levey, A. S., Beck, G. J., Caggiula, A. W., Hunsicker, L., Kusek, J. W., & Striker, G. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403313301301 · Cited by 2,328
Epidemiology and risk profile of heart failure
Bui, A. L., Horwich, T. B., & Fonarow, G. C. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.165 · Cited by 2,077
Levey, A. S., & Coresh, J. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60178-5 · Cited by 1,841
Fox, C. S., Matsushita, K., Woodward, M., Bilo, H. J., Chalmers, J., Heerspink, H. J. L., Lee, B. J., Perkins, R. M., Rossing, P., Sairenchi, T., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61350-6 · Cited by 1,401 · cited 1×
“CKD can often be a progressive condition, with proteinuria representing a significant risk factor for more rapid decline in kidney function [6].”
Heerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M., & Cherney, D. Z. I. (2016) · Circulation · doi:10.1161/circulationaha.116.021887 · Cited by 1,376 · cited 4×
“Natriuresis and altered tubular handling of filtered sodium may also have important modulatory effects on glomerular filtration rate (GFR) through reducing intraglomerular pressure [41, 43].”
InfluentialCombined angiotensin inhibition for the treatment of diabetic nephropathy
Fried, L. F., Emanuele, N., Zhang, J. H., Brophy, M., Conner, T. A., Duckworth, W., Leehey, D. J., McCullough, P. A., O'Connor, T., Palevsky, P. M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303154 · Cited by 1,169
Jafar, T. H., Schmid, C. H., Landa, M., Giatras, I., Toto, R., Remuzzi, G., Maschio, G., Brenner, B. M., Kamper, A., Zucchelli, P., et al. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-2-200107170-00007 · Cited by 1,092
Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes: A Systematic Review and Meta-analysis
Vasilakou, D., Karagiannis, T., Athanasiadou, E., Mainou, M., Liakos, A., Bekiari, E., Sarigianni, M., Matthews, D. R., & Tsapas, A. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-4-201308200-00007 · Cited by 911
Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment
Tonneijck, L., Muskiet, M. H. A., Smits, M. M., van Bommel, E. J., Heerspink, H. J. L., van Raalte, D. H., & Joles, J. A. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016060666 · Cited by 887
The hyperfiltration theory: A paradigm shift in nephrology
Brenner, B. M., Lawler, E. V., & Mackenzie, H. S. (1996) · Kidney International · doi:10.1038/ki.1996.265 · Cited by 868
Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin
Levin, A., Thompson, C. R., Ethier, J., Carlisle, E. J. F., Tobe, S., Mendelssohn, D., Burgess, E., Jindal, K., Barrett, B., Singer, J., et al. (1999) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(99)70118-6 · Cited by 841
Inzucchi, S. E., Zinman, B., Fitchett, D., Wanner, C., Ferrannini, E., Schumacher, M., Schmoor, C., Ohneberg, K., Johansen, O. E., George, J. T., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1096 · Cited by 740 · cited 1×
“Exploration of the EMPA-REG OUTCOME data has suggested that the increase in haematocrit caused by empagliflozin, a surrogate for reductions in plasma volume, was the intermediate clinical parameter with the largest mediating effect on the reduction in CV death [85].”
Self-citationFerrannini, E., Ramos, S. J., Salsali, A., Tang, W., & List, J. F. (2010) · Diabetes Care · doi:10.2337/dc10-0612 · Cited by 716
Ferrannini, E., Baldi, S., Frascerra, S., Astiarraga, B., Heise, T., Bizzotto, R., Mari, A., Pieber, T. R., & Muscelli, E. (2016) · Diabetes · doi:10.2337/db15-1356 · Cited by 712
The Failing Heart Relies on Ketone Bodies as a Fuel
Aubert, G., Martin, O. J., Horton, J. L., Lai, L., Vega, R. B., Leone, T. C., Koves, T., Gardell, S. J., Krüger, M., Hoppel, C. L., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.017355 · Cited by 707
Metra, M., & Teerlink, J. R. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31071-1 · Cited by 673
Glomerular hyperfiltration: definitions, mechanisms and clinical implications
Helal, I., Fick-Brosnahan, G. M., Reed-Gitomer, B., & Schrier, R. W. (2012) · Nature Reviews Nephrology · doi:10.1038/nrneph.2012.19 · Cited by 673
Kohan, D. E., Fioretto, P., Tang, W., & List, J. F. (2014) · Kidney International · doi:10.1038/ki.2013.356 · Cited by 652 · cited 2×
“Similarly, CKD Stages 3A and 3B have not been shown to modify the BP-lowering effect of dapagliflozin [61, 69].”
Perkovic, V., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Erondu, N., Shaw, W., Barrett, T. D., Weidner-Wells, M., Deng, H., Matthews, D. R., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30141-4 · Cited by 637
Vallon, V., & Thomson, S. C. (2017) · Diabetologia · doi:10.1007/s00125-016-4157-3 · Cited by 635 · cited 1×
“This equates to (cid:2) 50–80 g/day under normoglycaemic and modest hyperglycaemic conditions and perhaps > 100 g/day in people with diabetes and hyperfiltration [38].”
Follow-up of blood-pressure lowering and glucose control in type 2 diabetes
Zoungas, S., Chalmers, J., Neal, B., Billot, L., Li, Q., Hirakawa, Y., Arima, H., Monaghan, H., Joshi, R., Colagiuri, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407963 · Cited by 626 · cited 1×
“In people with diabetes, intensification of glycaemic control has been demonstrated to have moderately beneficial effects on markers of kidney disease progression compared with ‘standard’ regimens [14–16], and in the long-term this may translate into reduced risk of ESKD [17].”
SGLT2 Inhibitors May Predispose to Ketoacidosis
Taylor, S. I., Blau, J. E., & Rother, K. I. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1884 · Cited by 560
Zoungas, S., Arima, H., Gerstein, H. C., Holman, R. R., Woodward, M., Reaven, P., Hayward, R. A., Craven, T., Coleman, R. L., & Chalmers, J. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30104-3 · Cited by 529
Hallow, K. M., Helmlinger, G., Greasley, P. J., McMurray, J. J. V., & Boulton, D. W. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13126 · Cited by 499 · cited 4×
“780 mL) [70].”
InfluentialWanner, C., Lachin, J. M., Inzucchi, S. E., Fitchett, D., Mattheus, M., George, J., Woerle, H. J., Broedl, U. C., von Eynatten, M., & Zinman, B. (2018) · Circulation · doi:10.1161/circulationaha.117.028268 · Cited by 469
Self-citationBaker, W. L., Smyth, L. R., Riche, D. M., Bourret, E. M., Chamberlin, K. W., & White, W. B. (2014) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2014.01.007 · Cited by 452
Roden, M., Weng, J., Eilbracht, J., Delafont, B., Kim, G., Woerle, H. J., & Broedl, U. C. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70084-6 · Cited by 450
Chronic kidney disease management in the United Kingdom: NEOERICA project results
Stevens, P. E., O'Donoghue, D. J., de Lusignan, S., Van Vlymen, J., Klebe, B., Middleton, R., Hague, N., New, J., & Farmer, C. K. T. (2007) · Kidney International · doi:10.1038/sj.ki.5002273 · Cited by 434
Cherney, D. Z. I., Zinman, B., Inzucchi, S. E., Koitka-Weber, A., Mattheus, M., von Eynatten, M., & Wanner, C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30182-1 · Cited by 383
Self-citationRidderstråle, M., Andersen, K. R., Zeller, C., Kim, G., Woerle, H. J., & Broedl, U. C. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70120-2 · Cited by 378
Estimating the financial cost of chronic kidney disease to the NHS in England
Kerr, M., Bray, B., Medcalf, J., O'Donoghue, D. J., & Matthews, B. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs269 · Cited by 362
Canagliflozin slows progression of renal function decline independently of glycemic effects
Heerspink, H. J. L., Desai, M., Jardine, M., Balis, D., Meininger, G., & Perkovic, V. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016030278 · Cited by 361 · cited 2×
“Canagliflozin 100–300 mg/day has been compared with the sulfonylurea glimepiride in 1450 people with T2DM [72].”
Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition
Ferrannini, G., Hach, T., Crowe, S., Sanghvi, A., Hall, K. D., & Ferrannini, E. (2015) · Diabetes Care · doi:10.2337/dc15-0355 · Cited by 359
Renal sodium–glucose transport: role in diabetes mellitus and potential clinical implications
Bakris, G. L., Fonseca, V. A., Sharma, K., & Wright, E. M. (2009) · Kidney International · doi:10.1038/ki.2009.87 · Cited by 358
Familial Renal Glucosuria and SGLT2: From a Mendelian Trait to a Therapeutic Target
Santer, R., & Calado, J. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04010609 · Cited by 343
(2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30156-5 · Cited by 338
Associations between Kidney Function and Subclinical Cardiac Abnormalities in CKD
Park, M., Hsu, C.-Y., Li, Y., Mishra, R. K., Keane, M., Rosas, S. E., Dries, D., Xie, D., Chen, J., He, J., et al. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012020145 · Cited by 319
SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy
Wang, X. X., Levi, J., Luo, Y., Myakala, K., Herman-Edelstein, M., Qiu, L., Wang, D., Peng, Y., Grenz, A., Lucia, S., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.779520 · Cited by 306
Lv, J., Ehteshami, P., Sarnak, M. J., Tighiouart, H., Jun, M., Ninomiya, T., Foote, C., Rodgers, A., Zhang, H., Wang, H., et al. (2013) · Canadian Medical Association Journal · doi:10.1503/cmaj.121468 · Cited by 305
The Future Burden of CKD in the United States: A Simulation Model for the CDC CKD Initiative
Hoerger, T. J., Simpson, S. A., Yarnoff, B. O., Pavkov, M. E., Ríos Burrows, N., Saydah, S. H., Williams, D. E., & Zhuo, X. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.09.023 · Cited by 299 · cited 1×
“In high-income countries, the overall prevalence of chronic kidney disease (CKD) is (cid:2) 10% [1, 2] and this proportion is expected to rise as populations age further and diabetes mellitus becomes more common [3].”
Sha, S., Devineni, D., Ghosh, A., Polidori, D., Chien, S., Wexler, D., Shalayda, K., Demarest, K., & Rothenberg, P. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01406.x · Cited by 297
Blood Pressure Lowering Treatment Trialists' Collaboration (2013) · BMJ · doi:10.1136/bmj.f5680 · Cited by 263
de Boer, I. H., & for the DCCT/EDIC Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2113 · Cited by 254
Abdul-Ghani, M. A., DeFronzo, R. A., & Norton, L. (2013) · Diabetes · doi:10.2337/db13-0604 · Cited by 249
Cherney, D. Z. I., Cooper, M. E., Tikkanen, I., Pfarr, E., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Lund, S. S. (2018) · Kidney International · doi:10.1016/j.kint.2017.06.017 · Cited by 243
Fitchett, D., Butler, J., van de Borne, P., Zinman, B., Lachin, J. M., Wanner, C., Woerle, H. J., Hantel, S., George, J. T., Johansen, O. E., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx511 · Cited by 242
Self-citationJardine, M. J., Mahaffey, K. W., Neal, B., Agarwal, R., Bakris, G. L., Brenner, B. M., Bull, S., Cannon, C. P., Charytan, D. M., de Zeeuw, D., et al. (2017) · American Journal of Nephrology · doi:10.1159/000484633 · Cited by 234
Long-term evolution of cardiomyopathy in dialysis patients
Foley, R. N., Parfrey, P. S., Kent, G. M., Harnett, J. D., Murray, D. C., & Barre, P. E. (1998) · Kidney International · doi:10.1046/j.1523-1755.1998.00154.x · Cited by 226 · cited 1×
“About half of patients with advanced CKD have abnormal cardiac structure [25, 26], increasing to more than three-quarters by the time dialysis is initiated [26, 27].”
Why Do SGLT2 Inhibitors Inhibit Only 30–50% of Renal Glucose Reabsorption in Humans?
Liu, J. (., Lee, T., & DeFronzo, R. A. (2012) · Diabetes · doi:10.2337/db12-0052 · Cited by 225
Glomerular hyperfiltration: a marker of early renal damage in pre-diabetes and pre-hypertension
Palatini, P. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs037 · Cited by 224
Devineni, D., Curtin, C. R., Polidori, D., Gutierrez, M. J., Murphy, J., Rusch, S., & Rothenberg, P. L. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.88 · Cited by 217
Kohler, S., Zeller, C., Iliev, H., & Kaspers, S. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0573-0 · Cited by 195
Renin release from isolated juxtaglomerular apparatus depends on macula densa chloride transport
Lorenz, J. N., Weihprecht, H., Schnermann, J., Skott, O., & Briggs, J. P. (1991) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1991.260.4.f486 · Cited by 179
Verbrugge, F. H., Dupont, M., Steels, P., Grieten, L., Swennen, Q., Tang, W. H. W., & Mullens, W. (2014) · European Journal of Heart Failure · doi:10.1002/ejhf.35 · Cited by 171
Striepe, K., Jumar, A., Ott, C., Karg, M. V., Schneider, M. P., Kannenkeril, D., & Schmieder, R. E. (2017) · Circulation · doi:10.1161/circulationaha.117.029529 · Cited by 169
Canagliflozin: effects in overweight and obese subjects without diabetes mellitus
Bays, H. E., Weinstein, R., Law, G., & Canovatchel, W. (2014) · Obesity · doi:10.1002/oby.20663 · Cited by 166
Butler, J., Hamo, C. E., Filippatos, G., Pocock, S. J., Bernstein, R. A., Brueckmann, M., Cheung, A. K., George, J. T., Green, J. B., Januzzi, J. L., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.933 · Cited by 164
Self-citationPetrykiv, S., Sjöström, C. D., Greasley, P. J., Xu, J., Persson, F., & Heerspink, H. J. L. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.10180916 · Cited by 151
Shyangdan, D. S., Uthman, O. A., & Waugh, N. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-009417 · Cited by 149
SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review
Alicic, R. Z., Johnson, E. J., & Tuttle, K. R. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2018.03.022 · Cited by 135
Mancia, G., Cannon, C. P., Tikkanen, I., Zeller, C., Ley, L., Woerle, H. J., Broedl, U. C., & Johansen, O. E. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.07703 · Cited by 128 · cited 2×
“Given the effects of SGLT-2 inhibition on interstitial/plasma fluid volume [70] and BP [66, 71], a beneficial effect on cardiac pre-load and after-load is expected, and a reduction in the incidence of clinical outcomes among those with HF with reduced or preserved ejection fraction might be…”
Kent, S., Schlackow, I., Lozano-Kühne, J., Reith, C., Emberson, J., Haynes, R., Gray, A., Cass, A., Baigent, C., Landray, M. J., et al. (2015) · BMC Nephrology · doi:10.1186/s12882-015-0054-0 · Cited by 124
Self-citationCardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms
Staels, B. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.04.009 · Cited by 92
Haynes, R., Staplin, N., Emberson, J., G. Herrington, W., Tomson, C., Agodoa, L., Tesar, V., Levin, A., Lewis, D., Reith, C., et al. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.12.013 · Cited by 77
Self-citationAl-Jobori, H., Daniele, G., Cersosimo, E., Triplitt, C., Mehta, R., Norton, L., DeFronzo, R. A., & Abdul-Ghani, M. (2017) · Diabetes · doi:10.2337/db17-0100 · Cited by 67
Ogna, A., Ogna, V. F., Bochud, M., Guessous, I., Paccaud, F., Burnier, M., & Wuerzner, G. (2015) · European Journal of Nutrition · doi:10.1007/s00394-015-0923-0 · Cited by 58
Heart Failure With Preserved Ejection Fraction
Fang, J. C. (2016) · Circulation · doi:10.1161/circulationaha.116.022249 · Cited by 51
ACE and SGLT2 inhibitors: the future for non-diabetic and diabetic proteinuric renal disease
Perico, N., Ruggenenti, P. L., & Remuzzi, G. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.03.006 · Cited by 44
Tightening our understanding of intensive glycaemic control
Herrington, W. G., & Preiss, D. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30095-5 · Cited by 7
Self-citation
Research works printed but not linked: 2
- Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Guideline Development Work Group. KDIGO clinical practice guideline for lipid management in chronic kid- ney disease. Kidney Int Suppl 2013; 3: 263-26
- Empagliflozin (JardianceV R ) to be studied in chronic kidney disease. https://www.boehringer-ingelheim.com/press-release/emp agliflozin-be-studied-chronic-kidney-disease (29 August 2017, date last accessed)
Cited by
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab484 · Cited by 6,485
Self-citationCosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Self-citationEmpagliflozin in Patients with Chronic Kidney Disease
The EMPA-KIDNEY Collaborative Group (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2204233 · Cited by 2,754
Kalantar-Zadeh, K., Jafar, T. H., Nitsch, D., Neuen, B. L., & Perkovic, V. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00519-5 · Cited by 1,461
KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease
de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.019 · Cited by 1,399
Self-citation
Metadata
- Authors
- Herrington, W. G., Preiss, D., Haynes, R., von Eynatten, M., Staplin, N., Hauske, S. J., George, J. T., Green, J. B., Landray, M. J., Baigent, C., & Wanner, C.
- Affiliations
- University of Oxford (GB)
- Boehringer Ingelheim (Germany) (DE)
- Duke Medical Center (US)
- Universitätsklinikum Würzburg (DE)
- Corresponding author
- Herrington, William G
- ORCID
- Venue
- Clinical Kidney Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-10-25
- Volume
- 11
- Issue
- 6
- Pages
- 749-761
- ISSN
- 2048-8505 (ISSN-L)
- 2048-8513
- PMC
- PMC6275453
- OpenAlex
- W2898388822
- Cited by
- 237
- References
- 79
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 8 · 2023: 23 · 2022: 49 · 2021: 64 · 2020: 48 · 2019: 29 · 2018: 1
- FWCI
- 6.09
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Clinical Kidney Journal (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Medical Research Council
- Kidney Research UK
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- SGLT2 inhibitors, chronic kidney disease, EMPA-KIDNEY trial, cardiovascular outcomes, albuminuria, hyperfiltration, intraglomerular pressure, renal function decline, non-diabetic chronic kidney disease, renin-angiotensin system, heart failure hospitalization, cardiovascular mortality
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.